Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 481

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 3
Chunk 481
---
 models that require separation of beneficial conversion and cash conversion features from convertible instruments,
and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity.
It also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s
own equity and amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible
instruments. The guidance is effective for public business entities that meet the definition of a Securities and Exchange Commission filer,
excluding entities eligible to be smaller reporting companies as defined by the Securities and Exchange Commission, for fiscal years beginning
after December 15, 2021, including interim periods within those fiscal years. For all other entities, the guidance is effective for fiscal
years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier
than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted the guidance
as of January 1, 2024, which had no impact on the Company’s consolidated financial statements.

In November 2023, the FASB issued ASU 2023-07, Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The guidance includes the requirements that a public entity disclose,
on an annual and interim basis, significant segment expenses that are regularly provided to the chief operating decision maker and included
within each reported measure of segment profit or loss, the title and position of the chief operating decision maker, and an explanation
of how the chief operating decision maker uses the reported measure(s) of segment profit or loss in assessing segment performance and
deciding how to allocate resources. The guidance also requires that a public entity that has a single reportable segment provide all the
disclosures required by the guidance and all existing segment disclosures in ASC 280, Segment Reporting. The guidance is effective for
fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption
is permitted. A public entity should apply the amendments in the guidance retrospectively to all prior periods presented in the financial
statements. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant
segment expense categories identified and disclosed in the period of adoption. The Company adopted the guidance as of January 1, 202